Evidence map›Paper›PMID 40336024›Full record

ArticleOrphanet journal of rare diseases2025

Evolution of mobility, pain/discomfort, self-care, and mental health in patients with alpha-mannosidosis: an international caregiver and patient survey.

Karolina M Stepien, Sophie Thomas, Julia B Hennermann, Christina Lampe, Nicole M Muschol, Maria Juliana Ballesta-Martínez, Jordi Cruz, Mónica López-Rodríguez, Anneliese Barth, Martin Magner and 6 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Karolina M StepienAdult Inherited Metabolic Disorders, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Sophie ThomasThe Society for Mucopolysaccharide and Related Diseases, MPS House, Amersham, UK.
Julia B HennermannVilla Metabolica, University Medical Center Mainz, Mainz, Germany.
Christina LampeCentre for Rare Diseases, University Hospital of Giessen, Giessen, Germany.
Nicole M MuscholUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Maria Juliana Ballesta-MartínezHospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Jordi CruzAsociación MPS-Lisosomales España, Barcelona, Spain.
Mónica López-RodríguezHospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Anneliese BarthInstituto Fernandes Figueira /Fiocruz, Rio de Janeiro, Brazil.
Martin MagnerDepartment of Pediatrics and Inherited Metabolic Disorders, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Allan M LundCentre for Inherited Metabolic Diseases, Copenhagen University Hospital, Copenhagen, Denmark.
Vasilica PlaiasuRegional Center of Medical Genetics Bucharest, INSMC Alessandrescu-Rusescu, Bucharest, Romania.
Andrea BallabeniChiesi Farmaceutici S.p.A, Parma, Italy.
Francesca DonàChiesi Farmaceutici S.p.A, Parma, Italy.
Heather M MorganChiesi USA Inc., Boston, USA.
Nathalie GuffonReference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Hospices Civils de Lyon, Lyon, France. nathalie.guffon-fouilhoux@chu-lyon.fr.ORCID http://orcid.org/0000-0002-3052-2366

Funding

Chiesi Farmaceutici N/A
6 · The paper itself

Abstract

backgroundAlpha-mannosidosis is a rare recessive lysosomal storage disorder with progressive multi-systemic impacts. In the absence of standardized monitoring protocols, there is insufficient understanding of disease progression over time. This study explored the evolution of the burden of illness and quality of life (QoL) experienced by patients with alpha-mannosidosis via an international patient and caregiver-based survey. The online survey was distributed to adult patients/caregivers of patients ≥ 10 years old. It included visual analogue scales (VAS; timepoints 5 years ago and now), multiple choice, and open text questions. We report a subset of functional and QoL data: walking ability, pain/discomfort, ability to self-care, and mental health.

resultsAnalyses include 51 responses from 18 countries: 26 patients were on velmanase alfa enzyme replacement therapy (ERT), seven had been treated with hematopoietic stem cell transplantation (HSCT) and 18 were untreated patients (UP). Over 5 years, VAS scores showed the least decline in walking ability for HSCT patients (+ 0.1 ± 1.9) compared to patients receiving ERT (+ 0.7 ± 1.2) and UP (+ 1.8 ± 2.0). A trend towards improvement in pain was only observed for those on ERT (-0.2 ± 2.0), both for pediatric and adult patients. Ability to self-care improved for patients treated with HSCT (-1.0 ± 1.8) and slightly improved with ERT (-0.3 ± 1.5) but worsened for UP (+ 0.6 ± 0.9). Similarly, a trend towards improvement in mental health scores was observed for patients on ERT (-0.4 ± 2.2).

conclusionsAlpha-mannosidosis is associated with a substantial and progressive burden in UP, including deterioration in walking ability, pain, self-care and mental health. The survey results suggest that treatment with ERT or HSCT may slow this natural progression of alpha-mannosidosis, with these patients following a different disease trajectory to those solely receiving supportive care. This study could inform the natural pathway of alpha-mannosidosis to recognize patients' needs, courses of care, and the design of interventional studies.

Indexed as

alpha-MannosidosisPainAdolescentAdultCaregiversEnzyme Replacement TherapyFemaleHematopoietic Stem Cell TransplantationHumansMaleMental HealthMiddle AgedQuality of LifeSelf CareSurveys and QuestionnairesYoung AdultAlpha-mannosidosisMental healthPainSelf-careSurveyWalking

Identifiers

PMID40336024
PMCPMC12057280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.